Mixed cryoglobulinemia decelerates hepatocellular carcinoma development in hepatitis C patients with SVR by downregulating regulatory B cells: a 12-year prospective cohort study

OncoImmunology, Год журнала: 2025, Номер 14(1)

Опубликована: Фев. 26, 2025

How mixed cryoglobulinemia (MC) affects cancer risk in chronic hepatitis C patients with sustained virologic response (SVR) remains unclear. In a 12-year prospective study, post-SVR MC was assessed every 3‒6 months. Among the 891 SVR patients, 265 (29.7%) had baseline (24 weeks after completing anti-HCV therapy) MC, and cumulative incidence 19.7%. 73 who developed cancer, 37 (50.7%) hepatocellular carcinoma (HCC), following associated variables: for male sex, age alanine aminotransferase (ALT) levels; HCC, age, cirrhosis; non-HCC rheumatoid factor levels. mean time to HCC longer those than without (1545.4 ± 276.5 vs. 856.9 115.2 days, p = 0.014). Patients decreased circulating interleukin-10 (IL-10)-positive B cell (CD19+IL-10+cells/CD19+cells) (31.24 16.14 40.08 15.42%, 0.031), regulatory (Breg) (CD19+CD24hi CD27+cells/CD19+cells) (10.45 7.10 15.76 9.14%, 0.035), IL-10-positive Breg (CD19+CD24hiCD27+IL-10+cells/CD19+cells) (5.06 4.68 8.83 5.46%, 0.015) HCC-infiltrating (18.6 10 33.51 6.8%, 0.022) ratios but comparable T relative MC. conclusion, old elevated ALT levels or cirrhosis require intensive monitoring development, especially HCC. Tailored follow-up is needed according their which might downregulate Bregs decelerate development almost 2 years.

Язык: Английский

---

Combination therapy with vitamin E and ertugliflozin in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a randomized clinical trial

Irish Journal of Medical Science (1971 -), Год журнала: 2025, Номер unknown

Опубликована: Апрель 9, 2025

Язык: Английский

---

Rheumatoid factor levels indicate cryoglobulinemia severity in hepatitis B e antigen-negative hepatitis B virus carriers: a 7-year prospective cohort study

Hepatology International, Год журнала: 2024, Номер 19(1), С. 118 - 130

Опубликована: Дек. 19, 2024

Язык: Английский

---

Deciphering the Gut–Liver Axis: A Comprehensive Scientific Review of Non-Alcoholic Fatty Liver Disease

Livers, Год журнала: 2024, Номер 4(3), С. 435 - 454

Опубликована: Сен. 12, 2024

Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant global health issue. The condition is closely linked to metabolic dysfunctions such obesity and type 2 diabetes. gut–liver axis, bidirectional communication pathway between the gut, plays crucial role in pathogenesis of NAFLD. This review delves into mechanisms underlying exploring influence gut microbiota, intestinal permeability, inflammatory pathways. also explores potential therapeutic strategies centered on modulating microbiota fecal transplantation; phage therapy; use specific probiotics, prebiotics, postbiotics managing By understanding these interactions, we can better comprehend development advancement NAFLD identify targets.

Язык: Английский

---

Long‐term all‐cause mortality of metabolic‐dysfunction associated steatotic liver disease based on body weight phenotypes following acute myocardial infarction: A retrospective cohort study

Diabetes Obesity and Metabolism, Год журнала: 2024, Номер 27(2), С. 683 - 696

Опубликована: Ноя. 11, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity increases risk of cardiovascular disease. This cohort study examines the prognostic value MASLD, across body weight categories, in a secondary preventative acute myocardial infarction (AMI) cohort.

Язык: Английский

---